Latest Listings And Ipos News

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Yugo Metals has made promising progress with diamond drilling at its Sinjakovo project, intersecting silver-zinc-lead mineralisation, while securing $3.5 million in new funding and expanding its investor reach through a dual listing in Germany.

Lithium Plus Minerals has secured a 20-year mining lease for its Lei Lithium Project and progressed key environmental and mining studies, while also preparing exploration programs for its gold and critical minerals projects.

Solis Minerals has made a decisive leap in its Peruvian copper-gold exploration with the acquisition of the Cucho Project and a successful $5.9 million capital raise, setting the stage for an active 2026 drilling campaign.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

88 Energy Limited has significantly expanded its Alaskan North Slope acreage and progressed its farm-out strategy despite regulatory delays, while maintaining a solid cash position to support ongoing exploration.

LCL Resources reported promising high-grade gold-copper-silver assays from trenching in Papua New Guinea and is actively pursuing lower-risk jurisdiction assets while advancing its Colombian option agreement.

Australian United Investment Company Limited (AUI) has entered into a binding agreement to merge with Diversified United Investment Limited (DUI) through a share exchange scheme, aiming to enhance liquidity, reduce costs, and maintain dividends.

Hexima Limited reports a stable cash position of $1.4 million for the December quarter while exploring strategic options including a potential capital return to shareholders.

Novatti Group has reported its December quarter results, marking a fourth consecutive EBITDA positive quarter in its Payments AU/NZ business and securing $1 million in strategic growth funding. The company’s stake in AUDC has nearly doubled following a successful Pre-Series A funding round.

Diversified United Investment Limited (DUI) and Australian United Investment Company Limited (AUI) have agreed to merge, creating a $2.5 billion investment entity expected to deliver higher dividends and operational efficiencies.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.